UBS in Red at Open
UBS (NYSE:UBS) shares lost ground after the lender’s fourth-quarter results and up to $3 billion share buyback plans failed to impress.Switzerland’s largest bank on Tuesday reported net profit attributable to shareholders of $770 million, compared with a $483 million estimate in a company-provided consensus estimate and with a mean forecast of $886.4 million in a LSEG poll of analysts.Group revenue over the period hit $11.635 billion, versus analyst expectations of $11.64 billion in a LSEG analyst poll.The bank also announced plans to repurchase $1 billion of shares in the first half of 2025, along with up to an additional $2 billion over the second half of this year — but caveated that this target is subject to the lender achieving its “financial targets and the absence of material and immediate changes to the current capital regime in Switzerland.”The group further proposes a $0.90-per-share dividend for the 2024 financial year, up 29% year-on-year.Investment banking, according to news reports, shone over the fourth quarter, with underlying revenues up 37% year-on-year amid “strong growth” in global banking and global markets performance. The group’s global wealth management division logged a 10% hike in revenues over the fourth-quarter stretch, “largely driven by higher recurring net fee income, a decrease in negative other income and higher transaction-based income.”Shares of UBS opened down $2.38, or 6.8%, to $32.56.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


